The FDA has approved GlaxoSmithKline’s Trelegy Ellipta inhaler for asthma in adults, adding to its existing use in chronic obstructive pulmonary disease (COPD), stealing a march on rivals ...
Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler that’s prescribed for COPD. This article covers topics such as side effects, dosage ...
Trelegy is a key drug for GSK, and analysts predict peak sales in excess of $1billion. The company needs new revenues in respiratory diseases, as its ageing blockbuster inhaler Advair will face ...